Rumors are swirling about who President-elect Donald Trump may choose to lead the Food and Drug Administration, including a venture capitalist and a former agency official.
The CMS on Wednesday released data on the price history of 5,000 prescription drugs over five years, shedding light on the fastest rising source of healthcare costs in recent years.
President Barack Obama is expected to sign the massive lame-duck legislation that affects almost every corner of the healthcare industry.
British regulators fined U.S. drugmaker Pfizer and distributor Flynn Pharma a record $112.7 million Wednesday for increasing the cost of an epilepsy drug by as much as 2,600%.
Imagine not being able to afford one of life's great pleasures — sex. That's true for many older couples, doctors say. Soaring prices for prescription medicines for impotence and other problems have put the remedies out of reach for some.
Pfizer claims to be one of the first companies to use Watson's abilities for drug discovery and the first to use it for immuno-oncology—lucrative types of drugs that could be a major revenue source for Pfizer if its research succeeds.
Juno Therapeutics is halting the study of an experimental leukemia treatment for a second time after the death of two more patients. Two patients were reported dead in the closely watched drug trial in July.
Pharmaceutical company Mylan is refusing to testify at a congressional hearing next week on a settlement between the company and the Justice Department over its life-saving EpiPen.
Martin Shkreli promised last month to release Wu-Tang Clan's “Once Upon a Time in Shaolin” if Donald Trump took the White House. He made good on promise the day after the election by playing snippets of the album during a live Periscope video posted on Twitter.
Federal prosecutors on Thursday charged a former Valeant Pharmaceuticals executive and the ex-CEO of a specialty pharmacy for masterminding a multimillion fraud and kickback scheme that promoted the pharmacy's business for their own personal gain.
The American Medical Association joined the growing number of clinical organizations calling for value-based pricing for medications.
The internal watchdog at HHS has released a list of issues it hopes to tackle in 2017, and it shows a heightened focus on drug costs, an issue that has captivated the nation.